The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 - Therapy

Canadian Journal of Cardiology

Volumn 24, Issue 6, 2008, Pages 465-475

  Khan, Nadia A ^a,z   Hemmelgarn, Brenda ^b   Herman, Robert J ^b   Rabkin, Simon W ^a   McAlister, Finlay A ^c   Bell, Chaim M ^d,f   Touyz, Rhian M ^e   Padwal, Raj ^c   Leiter, Lawrence A ^f   Mahon, Jeff L ^g   Hill, Michael D ^b   Larochelle, Pierre ^h   Feldman, Ross D ⁱ   Schiffrin, Ernesto L ^j   Campbell, Norman R C ^b   Arnold, Malcolm O ^g   Moe, Gordon ^f   Campbell, Tavis S ^k   Milot, Alain ^l   Stone, James A ^b   Jones, Charlotte ^k   Ogilvie, Richard I ^m   Hamet, Pavel ⁿ   Fodor, George ^o   Carruthers, George ^p   Burns, Kevin D ^q   Ruzicka, Marcel ^q   deChamplain, Jacques ^h   Pylypchuk, George ^r,s   Petrella, Robert ^g   Boulanger, Jean Martin ^b   Trudeau, Luc ^t   Hegele, Robert A ^u   Woo, Vincent ^v   McFarlane, Phil ^w   Vallée, Michel ⁿ   Howlett, Jonathan ^x   Katzmarzyk, Peter ^y   Tobe, Sheldon ^v   Lewanczuk, Richard Z ^c   more..

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^f ST MICHAEL'S HOSPITAL   (Canada)

^g UNIVERSITY OF WESTERN ONTARIO   (Canada)

^h CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

ⁱ ROBARTS RESEARCH INSTITUTE   (Canada)

^j MCGILL UNIVERSITY   (Canada)

^k UNIVERSITY OF CALGARY   (Canada)

^l UNIVERSITÉ LAVAL   (Canada)

^m UNIVERSITY HEALTH NETWORK   (Canada)

ⁿ UNIVERSITÉ DE MONTRÉAL   (Canada)

^o UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^p UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^q UNIVERSITY OF OTTAWA   (Canada)

^r UNIVERSITY OF SASKATCHEWAN   (Canada)

^s YORK UNIVERSITY   (Canada)

^t MCGILL UNIVERSITY   (Canada)

^u WESTERN UNIVERSITY   (Canada)

^v UNIVERSITY OF MANITOBA   (Canada)

^w UNIVERSITY OF TORONTO   (Canada)

^x QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^y PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^z ST PAUL S HOSPITAL   (Canada)

more..

Author keywords

Antihypertensive drugs; Blood pressure; Guidelines; High blood pressure; Hypertension; Lifestyle interventions

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; FELODIPINE; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDAPAMIDE PLUS PERINDOPRIL; METHYLDOPA; METIROSINE; PHENOXYBENZAMINE; PLACEBO; PRAZOSIN; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VINCRISTINE;

AEROBIC EXERCISE; ALCOHOL CONSUMPTION; ANGINA PECTORIS; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CANADA; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COCHRANE LIBRARY; COMORBIDITY; CONTROLLED CLINICAL TRIAL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DIET SUPPLEMENTATION; DIETARY FIBER; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG DOSE TITRATION; DRUG INDICATION; DRUG MEGADOSE; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; HEALTH EDUCATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HIGH RISK PATIENT; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; HYPOKALEMIA; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; LIFESTYLE MODIFICATION; LOW DRUG DOSE; LOW FAT DIET; MEDLINE; MONOTHERAPY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHEOCHROMOCYTOMA; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; SODIUM RESTRICTION; STRESS MANAGEMENT; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE; WEIGHT CONTROL; HEALTH CARE QUALITY; MEDICAL EDUCATION; REVIEW; STANDARD; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; CANADA; EDUCATION, MEDICAL, CONTINUING; HUMANS; HYPERTENSION; PRACTICE GUIDELINES AS TOPIC; PROGRAM EVALUATION; TREATMENT OUTCOME;

EID: 46249084107     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(08)70620-2     Document Type: Article

References (28)

1. Murray CJ, Lauer JA, Hutubessy RC, et al. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: A global and regional analysis on reduction of cardiovascular-disease risk. Lancet 2003;361:717-25. (Erratum in 2005;366:204).
2. Yusuf S, Hawken S, Ounpuu S, et al; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 2004;364:937-52.
3. World Health Organization. Preventing chronic diseases: A vital investment. (Version current at April 29, 2008).
4. Patel A; ADVANCE Collaborative Group, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial. Lancet 2007;370:829-40.
5. Liu L, Zhang Y, Liu G, Li W, Zhang X, Zanchetti A; FEVER Study Group. The Felodipine Event Reduction (FEVER) Study: A randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens 2005;23:2157-72.
6. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53. (Errata in 2000 May 4;342:1376, 2000;342:748).
7. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41. (Errata in Lancet 2001;358:1556, 2002;359:2120).
8. Arima H, Chalmers J, Woodward M, et al; PROGRESS Collaborative Group. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: The PROGRESS trial. J Hypertens 2006;24:1201-8.
9. McAlister FA. The Canadian Hypertension Education Program - a unique Canadian initiative. Can J Cardiol 2006;22:559-64.
10. Whelton SP, Chin A, Xin X, He J. Effect of aerobic exercise on blood pressure: A meta-analysis of randomized, controlled trials. Ann Intern Med 2002;136:493-503.
11. Helmrich SP, Ragland DR, Leung RW, Paffenbarger RS Jr. Physical activity and reduced occurrence of non-insulin-dependent diabetes mellitus. N Engl J Med 1991;325:147-52.
12. Wannamethee SG, Shaper AG, Walker M. Changes in physical activity, mortality, and incidence of coronary heart disease in older men. Lancet 1998;351:1603-8.
13. Lee IM, Skerrett PJ. Physical activity and all-cause mortality: What is the dose-response relation? Med Sci Sports Exerc 2001;33(Suppl):S459-4.
14. Leitzmann MF, Park Y, Blair A, et al. Physical activity recommendations and decreased risk of mortality. Arch Intern Med 2007;167:2453-60.
15. Smith SC Jr, Blair SN, Bonow RO, et al. AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients With Atherosclerotic Cardiovascular Disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol 2001;38:1581-3.
16. Haskell WL, Lee IM, Pate RR, et al. Physical activity and public health: Updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Med Sci Sports Exerc. 2007;39:1423-34.
17. Touyz RM, Campbell N, Logan A, Gledhill N, Petrella R, Padwal R; Canadian Hypertension Education Program. The 2004 Canadian recommendations for the management of hypertension: Part III - lifestyle modifications to prevent and control hypertension. Can J Cardiol 2004;20:55-9.
18. Khan NA, McAlister FA, Lewanczuk RZ, et al; Canadian Hypertension Education Program. The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - therapy. Can J Cardiol 2005;21:657-72.
19. McAlister FA, Levine M, Zarnke KB, et al; Canadian Hypertension Recommendations Working Group. The 2000 Canadian recommendations for the management of hypertension: Part one - therapy. Can J Cardiol 2001;17:543-59.
20. Psaty BP, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NH. Health outcomes associated with various antihypertensive therapies used as first-line agents: A network meta-analysis. JAMA 2003;289:2534-44.
21. Khan NA, McAlister FA, Campbell NR, et al; Canadian Hypertension Education Program. The 2004 Canadian recommendations for the management of hypertension: Part II - therapy. Can J Cardiol 2004;20:41-54.
22. Rosendorff C, Black HR, Cannon CP, et al; American Heart Association Council for High Blood Pressure Research; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Epidemiology and Prevention. Treatment of hypertension in the prevention and management of ischemic heart disease: A scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007;115:2761-88. (Erratum appears in 2007;116:e121).
23. Flather MD, Yusuf S, Køber L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000;355:1575-81.
24. Lee VC, Rhew DC, Dylan M, Badamgarav E, Braunstein GD, Weingarten SR. Meta-analysis: Angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med 2004;141:693-704. (Erratum in 2005;42:391; dosage error in text).
25. Arnold JM, Liu P, Demers C, Dorian P, et al; Canadian Cardiovascular Society. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: Diagnosis and management. Can J Cardiol 2006;22:23-45. (Erratum in 2006;22:271).
26. McAlister FA, Zarnke KB, Campbell NR, et al; Canadian Hypertension Recommendations Working Group. The 2001 Canadian recommendations for the management of hypertension: Part two - therapy. Can J Cardiol 2002;18:625-41.
27. Khan NA, McAlister FA, Rabkin SW, et al; Canadian Hypertension Education Program. The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - therapy. Can J Cardiol 2006;22:583-93.
28. Sever PS, Dahlof B, Poulter NR, et al; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 2003;361:1149-58.